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AbstrACt
Objectives To investigate how depression is recognised 
in the year after child birth and treatment given in clinical 
practice.
Design Cohort study based on UK primary care electronic 
health records.
setting Primary care.
Participants Women who have given live birth between 
2000 and 2013.
Outcomes Prevalence of postnatal depression, depression 
diagnoses, depressive symptoms, antidepressant and non-
pharmacological treatment within a year after birth.
results Of 206 517 women, 23 623 (11%) had a record 
of depressive diagnosis or symptoms in the year after 
delivery and more than one in eight women received 
antidepressant treatment. Recording and treatment 
peaked 6–8 weeks after delivery. Initiation of selective 
serotonin reuptake inhibitors (SSRI) treatment has become 
earlier in the more recent years. Thus, the initiation rate 
of SSRI treatment per 100 pregnancies (95% CI) at 8 
weeks were 2.6 (2.5 to 2.8) in 2000–2004, increasing 
to 3.0 (2.9 to 3.1) in 2005–2009 and 3.8 (3.6 to 3.9) in 
2010–2013. The overall rate of initiation of SSRI within the 
year after delivery, however, has not changed noticeably. 
A third of the women had at least one record suggestive 
of depression at any time prior to delivery and of these 
one in four received SSRI treatment in the year after 
delivery. Younger women were most likely to have records 
of depression and depressive symptoms. (Relative risk 
for postnatal depression: age 15–19: 1.92 (1.76 to 2.10), 
age 20–24: 1.49 (1.39 to 1.59) versus age 30–34). The 
risk of depression, postnatal depression and depressive 
symptoms increased with increasing social deprivation.
Conclusions More than 1 in 10 women had electronic 
health records indicating depression diagnoses or 
depressive symptoms within a year after delivery and 
more than one in eight women received antidepressant 
treatment in this period. Women aged below 30 and from 
the most deprived areas were at highest risk of depression 
and most likely to receive antidepressant treatment.
IntrODuCtIOn  
Many women experience depression in the 
year after they have given birth. Postnatal 
depression affects an estimated 10%–19% of 
women, although the estimates vary substan-
tially between countries and settings.1–4 
Depression may have severe consequences for 
the mother and, in turn, have physical, cogni-
tive and emotional effects on their children’s 
development, continuing into later life.5–8 A 
report published by the London School of 
Economics estimated that perinatal depres-
sion, anxiety and psychosis carry a total long-
term cost to society of about £6.6 billion for 
each 1-year cohort of births in the UK.5 This 
is equivalent to a cost of just under £10 000 
for every single birth in the country. Nearly 
three-quarters (72%) of this cost relates to 
adverse impacts on the child rather than the 
mother.5 
Guidelines in both the USA and UK on 
antenatal and postnatal mental health recom-
mend that healthcare professionals should 
consider asking simple screening questions 
about current and past histories of depres-
sion, anxiety, alcohol and illicit drug use as 
part of a general discussion about mental 
health and well-being in pregnancy and the 
perinatal period.9 10 However, very limited 
information is available on when depression 
is recognised and how it is treated in clin-
ical practice in the year after women have 
given birth. For most women who experi-
ence depression in this period, primary care 
physicians would be a first point of contact. 
strengths and limitations of this study
 ► A major strength of this study is that we have access 
to a very large sample of primary care electronic 
health records of women who gave live birth.
 ► These records reflect clinical practice in UK primary 
care and are made prospectively.
 ► We considered a broad definition of depression 
on clinical evaluation in the year after delivery as 
there were no specific guidelines to how it should 
be recorded.
 ► This study may overestimate the number of women 
with postnatal depression compared with estimates 
based on a diagnostic interview and specific diag-
nostic instruments.
 ► Non-pharmacological treatment may not be well 
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In this study, we sought to obtain an overview of actual 
clinical practice in UK primary care by examining elec-
tronic health records on more than 200 000 women who 
have given live birth between 2000 and 2013. We followed 
the women for a year after delivery, and our aim was to 
examine how and when depression and depressive symp-
toms were recorded and treatment provided in general 




We used data from The Health Improvement Network. 
This is a large primary care database that provides anony-
mised longitudinal general practice (family practice) 
data on patients’ clinical and prescribing records and 
includes data from around 6% of the UK population. 
Diagnoses and symptoms are recorded by practice staff 
using Read codes which is a hierarchical coding system 
including more than 100 000 codes.11 12 The Read code 
system can be mapped to International Classification of 
Diseases, tenth revision (ICD-10), but in addition the 
Read codes include a number of symptoms and admin-
istrative codes.12 Prescriptions are issued electronically 
and directly recorded on the general practice computer 
systems. In addition, the database holds individual 
patient-level information about year of birth, date of 
registration, date of death and transfer out of the prac-
tice and information about social deprivation (quintiles 
of Townsend Deprivation Index scores). The Townsend 
scores are based on census data (2011) for car ownership, 
owner-occupation, overcrowding and unemployment in a 
patient’s postcode.13
Over 98% of the UK population are registered with a 
general practitioner (GP),14 and the UK primary care 
databases are broadly representative of the UK popula-
tion.15 16 While perinatal care is often shared between 
general practice staff and midwives, the GP remains 
responsible for women’s general medical care including 
continued prescribing of medicines such as antidepres-
sants. Some women may also receive care from local 
National Health Service mental health trusts, but trusts 
have limited prescribing budgets and for most women 
prescribing of psychotropic medication remains with the 
GP. Furthermore, after a few weeks after delivery, the care 
by the midwife ends and GPs are the first point of contact. 
Typically, women will consult their GP for a postnatal 
maternal check-up at 6–8 weeks after delivery.
study population
We used data from women who have given live birth 
between 1 January 2000 and 31 December 2013 and 
who were permanently registered with the same general 
practice for at least 1 year after delivery. As some women 
had more than one pregnancy and the risk of postnatal 
depression may be strongly correlated within women, we 
randomly selected one pregnancy per woman for our 
analyses.
Variables
We identified women with one or more records entered 
as a Read code in their primary care electronic health 
records which suggested they had depression, postnatal 
depression or symptoms of depression as well women 
on antidepressant and non-pharmacological treatment 
(referral to counselling and psychotherapy) in the year 
after they have given birth. Antidepressant treatment 
was classified as selective serotonin reuptake inhibitors 
(SSRI), tricyclic antidepressants (TCA) and other anti-
depressants. For TCA, we only considered treatment that 
was prescribed above treatment threshold for depres-
sion (eg, for amitriptyline we considered prescriptions 
of 75 mg and above), as lower doses may be prescribed 
for other reasons such as chronic pain. In addition, we 
included information on calendar year of delivery, age at 
delivery and social deprivation.
Data analysis
First, we estimated the prevalence of any records directly 
suggestive of depression (postnatal depression, depres-
sion diagnoses, depressive symptoms) as well as separate 
estimates for postnatal depression, depression diagnoses, 
depressive symptoms, antidepressant or non-pharmaco-
logical treatments within a year after giving birth. These 
estimates are reported in figure 1A. We then estimated 
how the records were inter-related. Inter-relations were 
reported as conditional frequencies, that is, the frequency 
of having a record of X given that one has a record of Y. 
These frequencies are reported in figure 1B. For example, 
the figure illustrates that 82% of those who had a diag-
nosis of depression also had a prescription of an SSRI. On 
the other hand, 31% of those who had a prescription of 
SSRI had a diagnosis of depression.
We estimated the timing of the recording within the 
follow-up year and report cumulative incidence curves (as 
one minus the Kaplan-Meier estimate). We also estimated 
smoothed daily hazards using a Gaussian process model17 
to visualise the daily changes in the timing of recording.
For each of the three depression outcomes (depression 
diagnosis, postnatal depression diagnosis and depression 
symptoms) and for SSRI and non-pharmacological treat-
ments, we used Poisson regression to model relative risks 
of having a record associated with age, calendar time and 
social deprivation (Townsend scores). Age was split into 
six age groups (15-19, 20-24, 25-29, 30-34, 35-39, 40-49) 
and calendar time into three periods (2000–2004, 2005–
2009, 2010–2013). 95% CI were computed using modi-
fied Poisson regression accounting for the clustering of 
women in general practices. We conducted supportive 
analyses stratified: (1) on whether women had any record 
suggestive of depression or treatment prior to delivery, 
(2) on whether the women had early or late records of 
depression or treatment. In the latter analyses, we catego-
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of depression or treatments before 42 days after delivery 
were considered as having an early record and women who 
had a record of depression or treatments after 42 days 
of delivery were considered as having a late record. We 
investigated whether this was associated with age, social 
deprivation, calendar time and any record suggestive of 
depression or treatment prior to delivery using logistic 
regression.
Patient and public involvement
Charlotte Walker, who is a mental health service user, 
has been involved with the original design of the study 
proposal and provided feedback on this manuscript and 
thus helped to shape the discussion of the paper from a 
service user’s perspective.
results
In total, 206 517 women were included in the study, 
and there were 23 623 (11%) with at least one record 
directly suggestive of depression (depression, postnatal 
depression or symptoms of depression) in the year after 
delivery. Of these women, there were 4% with a record of 
depression, 4% with a record of postnatal depression and 
5% with symptoms of depression (figure 1A). Of those 
women with a depression diagnosis, 2349/8815 (27%) 
also had depressive symptoms (figure 1B), and of those 
with postnatal depression diagnosis, 2005/9005 (22%) 
also had depressive symptoms (figure 1B). In contrast, 
there were 7408/11 318 (65%) women with a record of 
depressive symptoms without either a depression diag-
nosis or postnatal depression diagnosis.
The number of women with a record suggestive of 
depression continued to rise throughout the first year 
after delivery (figure 2). However, the recording of post-
natal depression levelled off after the first 3–4 months 
(figure 2A). For all types of records, there were some clear 
peaks in recording immediately after delivery and in the 
period between 6 and 8 weeks after delivery coinciding 
with the time of postnatal maternal check-up consulta-
tion (figure 2A).
There were 25 691 (12%) women with a record of 
antidepressant treatment. Women were predominantly 
prescribed SSRI (23 557, 92%) with TCA (1857, 7%) and 
other (2290, 8%) prescriptions being much less common. 
Of the women who had an SSRI prescription, there were 
31% who had a record of depression (figure 1B), 31% 
who had a record of postnatal depression (figure 1B) and 
33% who had depression symptoms (figure 1B). There 
were 6270 (27%) women with SSRI prescription without 
a record of either the depression diagnoses or symptom 
within a year after delivery. However, 4818 of these women 
had a record suggestive of depression or treatment prior 
to delivery leaving 1452 (6%) on SSRI treatment without 
a record suggestive of depression.
There were 6848 (3%) women with a record of referral 
for non-pharmacological treatment (figure 1A). Of the 
women receiving non-pharmacological treatment, there 
were 24% who had a record of depression (figure 1B), 
22% who had a record of postnatal depression (figure 1B) 
and 29% who had depression symptoms (figure 1B), but 
3064 (45%) with no records indicating depression, post-
natal depression or depressive symptoms. However, 2041 
of the the latter group of women had a record suggestive 
Figure 1 (A) Numbers of records of depressive diagnoses and symptoms, as well as treatment. (B) Conditional frequency of 
records: given that one has the condition on the y-axis, what is the frequency of having the condition on x-axis. For example, 
the figure illustrates that 82% of those who had a diagnosis of depression also had a prescription of an SSRI. On the other 
hand, 31% of those who had a prescription of SSRI had a diagnosis of depression. D/PND, either or both. D, depression 
diagnosis; D sym, depression symptom; NPT, non-pharmacological; PND, postnatal depression diagnosis; SSRI, selective 
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of depression or treatment prior to delivery leaving 1023 
(15%) with a referral for non-pharmacological treat-
ment, but without a record of depression. Of those with 
non-pharmacological treatment referral, 56% had SSRI 
prescription (figure 1B), whereas conversely only 16% 
with an SSRI prescription had a record of non-pharmaco-
logical treatment referral (figure 1B).
After the initial peak, the hazard for recording of post-
natal depression and SSRI prescription show a markedly 
decreasing trend, while the other records show a rela-
tively stable rate or slower decline (figure 2).
There were 64 283 (31%) women who had at least one 
record suggestive of depression or treatment at any time 
prior to delivery. The prevalence of depression and SSRI 
treatment after delivery was high among these women. 
Thus, there were 9666 (15%) with a record of depres-
sion or postnatal depression and 15 348 (24%) received 
SSRI treatment in the year after delivery. The figures were 
similar for women who have received SSRI treatment 
(n=40 178, 19%) at any time prior to delivery. Thus, there 
were 6940 (17%) with a record of depression or postnatal 
depression and 11 595 (29%) received SSRI treatment in 
the year after delivery.
Age, social deprivation and time
Younger women were much more likely to have a record 
of depressive diagnoses or symptoms compared with 
women aged 30 years or older. For example, women 
aged 15–19 years were nearly twice as likely to have a 
record of postnatal depression (RR, adjusted for social 
deprivation: 1.92 (1.76 to 2.10)) compared with women 
aged 30–34 years (table 1). There were no marked 
differences for women above the age of 30 (table 1). 
The pattern of SSRI treatment followed the same trends 
with nearly 1 in 5 women aged 15–19 receiving SSRI 
treatment in the first year after delivery (table 2) while 
for those aged above 30, it was 1 in 10 (table 2). Younger 
women were also more likely to receive non-pharmaco-
logical treatment than women aged 30 years or above 
(table 2).
The time to the initiation of SSRI treatment after the 
delivery has become earlier in the more recent years 
(figure 3). Thus, the initiation rate of SSRI treatment per 
100 pregnancies (95% CI) at 8 weeks were 2.6 (2.5 to 2.8) 
in 2000–2004, increasing to 3.0 (2.9 to 3.1) in 2005–2009 
and 3.8 (3.6 to 3.9) in 2010–2013. The overall rate of initi-
ation of SSRI within the year after delivery, however, has 
not changed noticeably (table 2). The rates of non-phar-
macological treatment have increased from 2.4 (2.2 to 
2.5) per 100 pregnancies in 2000–2004 to 3.8 (3.6 to 3.9) 
in 2010–2013 (table 2). The recording of both depres-
sion diagnosis and postnatal diagnosis has decreased 
substantially over time while the recording of symptoms 
increased in the earlier time period, but have remained 
relatively constant since 2005 (table 1).
Figure 2 Cumulative incidences and smoothed hazards for the records. Six and 8 weeks (6×7 and 8×7 days) are marked with 
a vertical grey line. Note the different y-axis scale for panels (A) and (B). D, depression; NPT, non-pharmacological treatment; 
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The risk of having a record of depression, postnatal 
depression and depressive symptoms increased with 
increasing social deprivation (table 1), and similar 
patterns were observed for both SSRI treatment and 
non-pharmacological treatment (table 2). Thus, nearly 
one in seven women from the most deprived areas 
received SSRI treatment within the first year after delivery 
in contrast to 1 in 11 women from the least deprived areas 
(table 2). Supportive analyses suggest that the effect of age 
is, in general, stronger among the women without records 
suggestive of depression or treatment prior to delivery 
than among women with prior records (online supple-
mentary appendix 1 STable 1-4). However, the effect of 
social deprivation and calendar time was similar in women 
with and without prior records of depression or treatment 
(online supplementary appendix 1 STable 1-4).
The women with early records (before 42 days after 
delivery) of depression, postnatal depression and depres-
sive symptoms were more likely to have a prior record of 
depression or treatment (adjusted OR estimates of 2.43 
(2.02 to 2.94), 1.58 (1.41 to 1.77) and 1.55 (1.37 to 1.76), 
respectively) (online supplementary appendix 1 STable 
5) and have delivered more recently (especially for post-
natal depression and depressive symptoms; respective 
adjusted OR estimates of 1.06 (0.87 to 1.28), 1.24 (1.08 
to 1.42) and 1.65 (1.38 to 1.97) for the three records 
for the 2010–2013 calendar period against the baseline 
2000–2005 period). The results were similar for women 
who had early records of SSRI treatment and non-phar-
macological treatment (adjusted OR estimates of 3.02 
(2.78 to 3.29) and 1.91 (1.62 to 2.27) for the prior record, 
respectively, and of 1.59 (1.46 to 1.74) and 1.36 (1.11 to 
1.68) for the recent time period) (online supplemen-
tary appendix 1 STable 6). No clear trends were observed 
in the effect of social deprivation or age group, except 
an indication of the youngest age group having a higher 
proportion of early recording for postnatal depression 
diagnosis (adjusted OR estimate of 1.43 (1.17 to 1.75)) 
(online supplementary appendix 1 STable 5).
DIsCussIOn
We found that 11% of women who had given live birth 
had a record suggestive of depression in their primary 
care electronic health records within the first year after 
delivery. There were some peaks in recording of depres-
sive diagnoses and symptoms and initiation of SSRI treat-
ment soon after delivery (6–8 weeks), coinciding with 
the time of postnatal maternal check-up consultations 
although they continued to be recorded throughout the 
first year after delivery. The time to the initiation of SSRI 
treatment after the delivery has become earlier in the 
more recent years although the overall rate of initiation 
of SSRI within the year after delivery has not changed. 
Women with records suggestive of depression or SSRI 
treatment prior to delivery were more likely to have a 
Table 1 Rates and relative risk estimates of depression diagnosis, postnatal depression diagnosis and depression symptoms 
in the first year after delivery for 206 517 women who gave birth between 2000 and 2013
Depression diagnosis Postnatal depression diagnosis Depression symptom
Rate per 100 Adjusted RR Rate per 100 Adjusted RR Rate per 100 Adjusted RR
Age group
  15–19 6.6 (6.1 to 7.1) 1.64 (1.50 to 1.81) 7.6 (7.1 to 8.1) 1.92 (1.76 to 2.10) 10.6 (10.0 to 
11.2)
2.10 (1.95 to 2.27)
  20–24 6.1 (5.9 to 6.4) 1.59 (1.47 to 1.71) 5.8 (5.5 to 6.0) 1.49 (1.39 to 1.59) 8.1 (7.7 to 8.4) 1.63 (1.54 to 1.73)
  25–29 4.5 (4.3 to 4.7) 1.22 (1.15 to 1.30) 4.6 (4.4 to 4.8) 1.21 (1.14 to 1.29) 5.5 (5.3 to 5.7) 1.18 (1.12 to 1.24)
  30–34 3.6 (3.4 to 3.7) 1 3.8 (3.6 to 3.9) 1 4.4 (4.3 to 4.6) 1
  35–39 3.5 (3.3 to 3.7) 1.00 (0.93 to 1.06) 3.5 (3.3 to 3.6) 0.92 (0.86 to 0.98) 4.3 (4.1 to 4.4) 0.97 (0.92 to 1.02)
  40–49 3.1 (2.8 to 3.5) 0.92 (0.81 to 1.03) 3.2 (2.8 to 3.5) 0.86 (0.77 to 0.97) 4.7 (4.3 to 5.1) 1.06 (0.96 to 1.17)
Calendar period
  2000–2004 5.7 (5.5 to 5.9) 1 5.8 (5.6 to 6.0) 1 4.4 (4.2 to 4.6) 1
  2005–2009 4.2 (4.0 to 4.3) 0.71 (0.66 to 0.77) 4.4 (4.2 to 4.5) 0.73 (0.69 to 0.78) 6.0 (5.8 to 6.2) 1.31 (1.21 to 1.42)
  2010–2013 3.5 (3.3 to 3.6) 0.58 (0.53 to 0.63) 3.4 (3.3 to 3.5) 0.56 (0.52 to 0.60) 5.6 (5.4 to 5.8) 1.21 (1.11 to 1.32)
Townsend Deprivation Index quintile
  1 3.2 (3.0 to 3.3) 1 3.7 (3.5 to 3.9) 1 4.1 (3.9 to 4.2) 1
  2 3.6 (3.4 to 3.8) 1.14 (1.05 to 1.22) 4.1 (3.9 to 4.2) 1.09 (1.01 to 1.17) 4.5 (4.3 to 4.7) 1.07 (1.00 to 1.15)
  3 4.1 (3.9 to 4.3) 1.26 (1.16 to 1.36) 4.3 (4.1 to 4.5) 1.12 (1.04 to 1.21) 5.3 (5.1 to 5.5) 1.19 (1.10 to 1.28)
  4 5.1 (4.9 to 5.3) 1.51 (1.38 to 1.64) 4.8 (4.6 to 5.0) 1.20 (1.11 to 1.30) 6.6 (6.4 to 6.9) 1.42 (1.31 to 1.53)
  5 6.0 (5.7 to 6.3) 1.69 (1.53 to 1.87) 5.3 (5.0 to 5.5) 1.26 (1.13 to 1.39) 7.7 (7.4 to 8.0) 1.56 (1.42 to 1.72)
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subsequent record and/or treatment after delivery. Like-
wise, of women with records of depression and treatment 
after delivery those with an early record (before 42 days 
after delivery) were more likely to have prior records of 
depression or treatments than women with later records 
(after 42 days of delivery).
Younger women were more likely to have a record 
suggestive of depression compared with women aged 30 
years or older and the pattern of SSRI initiation followed 
the same trend with nearly one in five women aged 
between 15 and 19 years receiving SSRI treatment in the 
first year after delivery. The risk of depression increased 
with increasing social deprivation, and similar patterns 
were observed for both SSRI treatment and non-pharma-
cological treatment.
strengths and limitations
A major strength of this study is that we have access to 
a very large sample of primary care electronic health 
records of women who gave live birth. These records 
reflect clinical practice in UK primary care and were made 
prospectively and therefore are not subject to recall bias. 
We considered a broad definition of depression based on 
clinical evaluation in the year after delivery as there are 
no specific guidelines to how it should be recorded in this 
period in primary care. Thus, we included women who 
had a specific diagnosis of postnatal depression, as well as 
women with records of depression diagnosis and symp-
toms, which may overestimate the number of women with 
postnatal depression compared with estimates based on a 
diagnostic interview and specific diagnostic instruments.
We are also aware that the indications for SSRI 
prescribing are broader than depression, and some 
Table 2 Rates and relative risk estimates of SSRI prescription and non-pharmacological treatment in the first year after 
delivery for 206 517 women who gave birth between 2000 and 2013
SSRI prescription Non-pharmacological treatment
Rate per 100 Adjusted RR Rate per 100 Adjusted RR
Age group
  15–19 18.8 (18.0 to 19.5) 1.78 (1.68 to 1.88) 4.9 (4.5 to 5.4) 1.55 (1.41 to 1.72)
  20–24 15.9 (15.5 to 16.4) 1.54 (1.47 to 1.61) 4.4 (4.1 to 4.6) 1.38 (1.28 to 1.49)
  25–29 11.7 (11.5 to 12.0) 1.18 (1.14 to 1.23) 3.3 (3.2 to 3.5) 1.11 (1.04 to 1.18)
  30–34 9.6 (9.4 to 9.8) 1 2.9 (2.8 to 3.0) 1
  35–39 9.3 (9.1 to 9.6) 0.99 (0.95 to 1.03) 2.9 (2.7 to 3.0) 0.99 (0.92 to 1.07)
  40–49 9.6 (9.0 to 10.1) 1.01 (0.94 to 1.07) 3.1 (2.7 to 3.4) 1.05 (0.93 to 1.19)
Calendar period
  2000–2004 11.4 (11.1 to 11.7) 1 2.4 (2.2 to 2.5) 1
  2005–2009 11.3 (11.1 to 11.6) 0.97 (0.93 to 1.01) 3.5 (3.3 to 3.6) 1.43 (1.30 to 1.57)
  2010–2013 11.5 (11.2 to 11.7) 0.96 (0.92 to 1.01) 3.8 (3.6 to 3.9) 1.54 (1.38 to 1.71)
Townsend Deprivation Index quantile
  1 8.9 (8.7 to 9.2) 1 2.7 (2.5 to 2.8) 1
  2 10.0 (9.7 to 10.3) 1.09 (1.04 to 1.14) 3.0 (2.9 to 3.2) 1.10 (1.00 to 1.20)
  3 11.3 (11.0 to 11.6) 1.19 (1.14 to 1.25) 3.3 (3.1 to 3.4) 1.14 (1.04 to 1.25)
  4 13.1 (12.7 to 13.4) 1.33 (1.25 to 1.40) 3.8 (3.6 to 4.0) 1.29 (1.17 to 1.42)
  5 15.2 (14.8 to 15.6) 1.47 (1.38 to 1.57) 4.2 (3.9 to 4.4) 1.36 (1.22 to 1.52)
Adjusted by age group, calendar period and Townsend Deprivation Index.
RR, relative risk; SSRI, selective serotonin reuptake inhibitor.
Figure 3 Cumulative incidence of selective serotonin 
reuptake inhibitor (SSRI) in three calendar periods. Six and 
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women in our study may have received SSRI for treatment 
for other indications, for example, anxiety. Yet, there is 
often an overlap between depression and anxiety,18 and 
we chose, therefore, to include initiation of all SSRI 
prescriptions in our study. Our estimates of referral for 
non-pharmacological treatment were relatively low. This 
may reflect a limited accessibility to non-pharmacological 
treatment, but it is also important to be aware that often 
in clinical practice the booking system for referrals is not 
directly linked to electronic health records, and general 
practice staff will need to enter these referrals separately 
in the patient records. Furthermore, it is increasingly 
possible for women to self-refer themselves to psycholog-
ical therapies through the ‘Improving Access to Psycho-
logical Therapies’ scheme in the UK (https://www. 
england. nhs. uk/ mentalhealth/ adults/ iapt/). Therefore, 
it is likely that our study underestimates the actual referral 
rates for non-pharmacological treatments.
Comparisons to existing evidence
Our summary estimate of postnatal depression, depres-
sion and symptoms of depression in the year after delivery 
(11%) was within the lower end of the range of previous 
prevalence estimates (10%–19%).2–4 Gavin et al esti-
mated point prevalence of minor and major depression 
was highest in the third month after delivery at 12.9%, 
although the CIs were wide.2 The results of our study 
suggest a peak in depression records and antidepressant 
treatment within 6–8 weeks after delivery, coinciding with 
the time of postnatal check-up consultations.
Our findings of increase in the use of symptoms codes 
as opposed to diagnostic codes for recording of depres-
sion reflect previous findings on recording of depression 
in primary care in general.19 Rait et al suggest GPs’ coding 
may be linked to the perceived severity of depression, 
with symptom codes being used for milder depression. 
Alternatively, this move towards recording of symptoms 
and less specific terms may be perceived as less stigma-
tising for individuals.19
Nearly one out five women in our study had a record 
suggestive of depression and/or SSRI treatment records 
prior to delivery. Of these women, 17% had additional 
records of depression and more than a quarter received 
SSRI treatment in the year after delivery. Prior depres-
sion has long been recognised as one of the strongest risk 
factors for depression in the year after delivery.1–3 20 We 
also found that women who sought help early (before 42 
days after delivery) were more likely to have had a prior 
record of depression or treatment. They might be better 
at recognising the symptoms earlier on than women 
without prior experience. Thus, a qualitative systematic 
review of help-seeking barriers by Dennis and Chung-Lee 
concluded that lack of knowledge about postpartum 
depression or the acceptance of myths was a significant 
help-seeking barrier and rendered mothers unable to 
recognise the symptoms of depression.21
Many women discontinue antidepressant treatment in 
pregnancy.22 23 A few studies suggest that these women 
are at higher risk of relapse,24 but it is difficult to judge 
in observational settings and further research is needed 
to understand the role of antidepressant treatment in 
prevention of depression in the year after delivery.
Increased risk of postnatal depression among teenage 
mothers is well recognised with prevalence estimates as 
high as 26%.25 Our study demonstrated that the level 
of recording of depressive diagnoses and symptoms 
continued to be higher for women right up to the age of 
30, whereas no marked difference was found for women 
above the age of 30. Previous meta-analyses of postnatal 
depression have failed to recognise this ‘L-shaped’ differ-
ence in risk of postnatal depression with age.1 3 In contrast 
to our findings, a recent Canadian study on women aged 
20–44 years based on the Canadian Community Health 
Survey suggests that there is a ‘U-shaped’ relationship 
with age and postnatal depression. Thus, they found that 
the prevalence of depression in women who had recently 
delivered was significantly higher in women aged 40–44 
years than in women aged 30–35 years (adjusted OR 3.72; 
95% CI 2.15 to 6.41).26
There is some evidence that socioeconomic status is 
associated with prevalence of postnatal depression.2 3 8 27 
The results of a meta-regression analysis suggest that the 
prevalence of major depression is similar among socio-
economic status groups, but that minor depression may 
be more prevalent among lower socioeconomic status 
groups.2 While we were unable to distinguish directly 
between diagnosis of major and minor depression, we 
observed a clear gradient with increasing level of depriva-
tion across all measures of depression and treatments. An 
even stronger socioeconomic gradient in SSRI treatment 
was found among general population of adult women 
in the UK. Hence, women from the most deprived areas 
were 64% more likely to have been initiated on SSRI 
treatment compared with women from the least deprived 
areas.28
Our study reflects women’s primary care electronic 
health records. For women to have records of depression, 
it requires that they have consulted their GP. However, 
some women may be reluctant to seek help and unwilling 
to disclose or discuss their problem because of fear of 
stigma, negative perceptions of them as a mother or fear 
that their baby might be taken into care.6 21 29 Investigators 
and clinicians should also be aware of the potential differ-
ences in the way women express postpartum depression 
and that it may differ for women of different educational 
backgrounds.30 Likewise, some healthcare professionals 
may miss or misdiagnose postnatal depression in the 
period soon after birth6 and estimates based on primary 
care health records may underestimate the ‘true’ prev-
alence of postnatal depression. Our study clearly shows 
that for many women depression and depressive symp-
toms were ‘picked up’ and treatment initiated at the time 
of the maternal check-up consultation in accordance to 
guidelines on antenatal and postnatal mental health-
care.29 Yet, our results have also revealed that depression 
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emphasise the need for healthcare professionals to be 
alert to signs and symptoms of depression throughout the 
first year after delivery. Indeed, a recent systematic review 
suggested that screening postpartum women for depres-
sion may reduce depressive symptoms in women with 
depression and reduce the prevalence of depression.31
COnClusIOns
More than 1 in 10 women had electronic health records 
indicating depression or depressive symptoms within a 
year after delivery, and more than one in eight women 
received antidepressant treatment in this period. Women 
aged below 30 and from the most deprived areas were at 
the highest risk of depression and most likely to receive 
antidepressant treatment.
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